BioCentury
ARTICLE | Company News

Actelion sales and marketing update

July 29, 2013 7:00 AM UTC

Actelion disclosed in its 1H13 earnings that at the end of 2Q13 it launched 0.5 and 1.5 mg epoprostenol as Epoprostenol ACT in Japan to treat pulmonary arterial hypertension (PAH). The formulation of...